A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

Phase 4 Completed 99 enrolled Janssen Pharmaceutica N.V., Belgium

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the maintained effectiveness of long-acting injectable risperidone (RISPERDAL® CONSTA™) compared with the previous treatment with oral olanzapine in non-acute subjects with schizophrenia or schizoaffective disorder considered in need of a therapy change.

Timeline

Start: 2005-03
Primary completion: 2007-07
Completion: 2007-07

Publications

Rosa F, Schreiner A, Thomas P, Sherif T. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Risperidone	Other / unclassified	2 mg	Intramuscular
Subject	Risperidone	Other / unclassified	25 mg	Intramuscular
Subject	Risperidone	Other / unclassified	37.5 mg	Intramuscular
Subject	Risperidone	Other / unclassified	50 mg	Intramuscular

A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

Summary

Timeline

Publications

Drugs

Indications